BEGIN:VCALENDAR
PRODID:-//Columba Systems Ltd//NONSGML CPNG/SpringViewer/ICal Output/3.3-
 M3//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20140320T100203Z
DTSTART:20140401T120000Z
DTEND:20140401T130000Z
SUMMARY:Hyaluronan hydrogels in regenerative medicine
UID:{http://www.columbasystems.com/customers/uom/gpp/eventid/}vs4-hsx0mpz
 1-oxise8
DESCRIPTION:Faculty and student entrepreneurs create innovation and impac
 t and make people’s lives better. Their scholarly activities in translat
 ional research\, teaching\, and service bring the fruits of technology t
 o the public. The translational imperative is clear: embrace complexity\
 , engineer versatility\, but deliver simplicity. The development of clin
 ical biomaterials for regenerative medicine will be an example of implem
 enting this imperative.                                                 
                    \nWe created a synthetic extracellular matrix (sECM) 
 from hyaluronic acid (HA) that affords highly reproducible\, manufactura
 ble\, approvable\, and affordable biomaterials. These injectable clinica
 l materials are used for delivery\, retention of progenitor cells for ce
 ll therapy. These injectable clinical materials are now commercial produ
 cts three fields of use: (i) human medical devices\, (ii) cell therapy a
 nd research tools for 3-D cell culture\, and (iii) veterinary wound care
  and adhesion prevention.                                               
                 \n\n(1)	G. D. Prestwich\, “Culture of impact: faculty as
  mentors for student entrepreneurs\,” Science Translational Medicine 5\,
  169ed2 (2013).\n\n(2)	J. Burdick\, G. D. Prestwich\, “Hyaluronic Acid H
 ydrogels for Biomedical Applications”\, Advanced  Materials 23\, H41-H56
  (2011).\n\n(3)	G. D. Prestwich\, I. Erickson\, T. I. Zarembinski\, M. W
 est\, and W. P. Tew. “The Translational Imperative: Making Cell Therapy 
 Simple and Effective\,” Acta Biomaterialia\, 8\, 4200-4207 (2012). \n\n\
 n\nGlenn D. Prestwich is Presidential Professor of Medicinal Chemistry a
 nd Presidential Special Assistant for Faculty Entrepreneurism at the Uni
 versity of Utah. He created and directs the Entrepreneurial Faculty Scho
 lars program at Utah. His research encompasses drug discovery in cell si
 gnaling\, synthetic matrices for regenerative medicine\, and glycosamino
 glycan derivatives as anti-inflammatory agents. He co-founded 9 companie
 s\, including Echelon Biosciences\, Glycosan BioSystems\, Sentrx Animal 
 Care\, GlycoMira Therapeutics\, Deuteria Agrochemicals\, and Metallosens
 ors. In 2013\, he was inducted as a Fellow of the National Academy of In
 ventors. Other honors include the Utah Governor’s Medal for Science and 
 Technology for 2006\, the 1998 Paul Dawson Biotechnology Award & the 200
 8 Volwiler Research Award of the American Association of Colleges of Pha
 rmacy\, the 2010 University of Utah Distinguished Scholarly and Creative
  Research Award\, and the 2014 U of Utah Distinguished Innovation and Im
 pact Award . During 37 years as a faculty member\, he has published over
  640 technical papers\, patents\, and book chapters\, and has trained ov
 er 125 postgraduate scientists. He is also a pilot and sings first tenor
  in the Utah Symphony Chorus. 
STATUS:TENTATIVE
TRANSP:TRANSPARENT
CLASS:PUBLIC
LOCATION:Michael Smith LT\, Michael Smith Building\, Manchester
END:VEVENT
END:VCALENDAR